Rivaroxaban vs. Warfarin in Japanese patients with atrial fibrillation - The J-ROCKET AF study

Circulation Journal

Volumn 76, Issue 9, 2012, Pages 2104-2111

  Hori, Masatsugu ^a   Matsumoto, Masayasu ^a   Tanahashi, Norio ^b   Momomura, Shin ichi ^c   Uchiyama, Shinichiro ^d   Goto, Shinya ^e   Izumi, Tohru ^f   Koretsune, Yukihiro ^g   Kajikawa, Mariko ^h   Kato, Masaharu ^h   Ueda, Hitoshi ^h   Iwamoto, Kazuya ^h   Tajiri, Masahiro ^h  

^a HIROSHIMA UNIVERSITY   (Japan)

^b SAITAMA MEDICAL UNIVERSITY INTERNATIONAL MEDICAL CENTER   (Japan)

^c JICHI MEDICAL UNIVERSITY   (Japan)

^d TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^e TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g OSAKA NATIONAL HOSPITAL   (Japan)

^h BAYER YAKUHIN LTD   (Japan)

Author keywords

Anticoagulants; Atrial fibrillation; Japanese; Prevention; Stroke

Indexed keywords

PLACEBO; RIVAROXABAN; WARFARIN;

ADULT; AGED; ARTICLE; BACKACHE; BLEEDING; BRAIN HEMORRHAGE; CONTROLLED STUDY; CONTUSION; DIABETES MELLITUS; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EMBOLISM; EPISTAXIS; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; GINGIVA BLEEDING; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEMARTHROSIS; HEMATOMA; HEMATURIA; HUMAN; INTRAOCULAR HEMORRHAGE; JAPANESE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECTUM HEMORRHAGE; RHINOPHARYNGITIS; RISK; SIDE EFFECT; STROKE; SUBCUTANEOUS HEMORRHAGE; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; DOUBLE-BLIND METHOD; EMBOLISM; FEMALE; HUMANS; INTRACRANIAL HEMORRHAGES; MALE; MIDDLE AGED; MORPHOLINES; PROSPECTIVE STUDIES; STROKE; THIOPHENES; WARFARIN;

EID: 84864379749     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-12-0454     Document Type: Article

References (13)

1. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008; 133: 160S-198S.
2. Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006; 114: 700-752.
3. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-891.
4. Japanese Circulation Society Joint Working Group. Guidelines for pharmacotherapy of atrial fibrillation (JCS 2008): Digest version. Circ J 2010; 74: 2479-2500.
5. Atarashi H, Inoue H, Okumura K, Yamashita T, Kumagai N, Origasa H. Present status of anticoagulation treatment in Japanese patients with atrial fibrillation. Circ J 2011; 75: 1328-1333.
6. Cheung CM, Tsoi TH, Huang CY. The lowest effective intensity of prophylactic anticoagulation for patients with atrial fibrillation. Cerebrovasc Dis 2005; 20: 114-119.
7. Yasaka M, Minematsu K, Yamaguchi T. Optimal intensity of international normalized ratio in warfarin therapy for secondary prevention of stroke in patients with non-valvular atrial fibrillation. Intern Med 2001; 40: 1183-1188.
8. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993; 69: 236-239.
9. Hirsh J. Oral anticoagulant drugs. N Engl J Med 1991; 324: 1865-1875.
10. Hori M, Connolly SJ, Ezekowitz MD, Reilly PA, Yusuf S, Wallentin L. Efficacy and safety of dabigatran vs. warfarin in patients with atrial fibrillation: Sub-analysis in Japanese population in RE-LY trial. Circ J 2011; 75: 800-805.
11. Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: An analysis of the RE-LY trial. Lancet 2010; 376: 975-983.
12. Amouyel P, Mismetti P, Langkilde LK, Jasso-Mosqueda G, Nelander K, Lamarque H. INR variability in atrial fibrillation: A risk model for cerebrovascular events. Eur J Intern Med 2009; 20: 63-69.
13. Fox KAA, Piccini JP, Wojdyla D, Becker RC, Halperin JL, Nessel CC, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J 2011; 32: 2387-2394.